http://localhost:8080/xmlui/handle/123456789/7474 Sun, 12 Apr 2026 21:27:08 GMT 2026-04-12T21:27:08Z http://localhost:8080/xmlui/handle/123456789/8325 Antimicrobial utilization pattern among pediatric inpatients of a tertiary care hospital in Central Gujarat Patel, Nirav; Patel, Devanshu J; Desai, Haresh Background: Drug utilization studies may help to measure various aspects such as disease pattern, medicine use, and prescribing patterns. Aim and Objective: The aim of the study was to evaluate the drug utilization pattern of antimicrobials prescribed to the pediatric inpatients at a tertiary care hospital. Materials and Methods: The study was prospective and observational based involving 200 pediatric inpatients of Parul Sevashram Hospital, Vadodara, Gujarat. Relevant information was obtained from the interview as well the hospital case record. Structured and pre-tested formats were prepared for compiling the data. Results: The majority of the patients (43.5%) were in the age group between 2 and 12 years. The most common indications for antimicrobial use included gastrointestinal diseases (22%), respiratory diseases (17.5%), and genitourinary diseases (13.5%). Cephalosporins (65.5%) were most frequently prescribed antimicrobials followed by aminoglycosides (40%). 73.3% of antimicrobials were prescribed by branded names. The average number of antimicrobials prescribed per patient was 2.21. 93.4% of antimicrobials have been included in the World Health Organization Model List of Essential Medicines. A total of 13 adverse drug reactions were reported from prescribed antimicrobials. Conclusions: Medicine utilization assessment can facilitate rational use of medicines in pediatric patients. Tue, 01 Oct 2019 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/8325 2019-10-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/8253 In sillico analysis, synthesis, and biological evaluation of triazole derivatives as a H1 receptor antagonist Badeliya, Sandip Background: Histamine, a biological amine, is considered as a principal mediator of many pathological processes regulating several essential events in allergies and autoimmune diseases. Numerous derivatives have been developed that strive with histamine at H1 receptor and prevent binding of histamine at H1 receptor thus prevent allergic reactions. Molecules containing triazole ring fused with six-membered ring systems are found to possess broad applications in the field of medicine and industry. The present study is an attempt to characterize the impact of the nature of the substituent introduced at the 5 positions of the-4H-1,2,4-triazole-3-thiol on their capacities to bind with H1 receptor. Methods: Molecular docking (PDB ID: 3RZE) revealed that synthesized derivatives and target proteins were actively involved in binding with Tyr-108, Thr-112, Ala-216, and Phe432 subunits. The pharmacophore model new 5-(4-substituted phenyl)-4-(phenylamino)- 4-H-1,2,4-triazole-3-thiols (5a-5h) were designed and evaluated for H1-blocking activity using isolated segments from the guinea pig ileum. Results: According to in silico analysis, all the compounds have a topological polar surface area (TPSA) less than 140 Å squared, so they tend to a good penetration in cell membranes. The results show that most of the compounds are non-inhibitors of CYP450 substrates that play a fundamental role in drug metabolism. Compounds 5d (50.53±12.03), 5h (50.62±12.33) and 7a (55.07±12.41) are more active than others. Conclusion: Finally, these derivatives were screened for H1 receptor antagonist activity using guinea pig ileum taking chlorpheniramine Wed, 01 Apr 2020 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/8253 2020-04-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/8252 Natural perspective for Management of drug resistant Tuberculosis: A Review Martolia, Jaya; Soni, Hardik; Tandel, Falguni Tuberculosis is a serious health problem in many regions of the world, especially in developing countries. Globally around 2 billion people are suffering from Mycobacterium tuberculosis and every year at approximate 10 million people developed TB disease and 1.3 million deaths. Worldwide approx.160684 cases of MDR/RR-TB were identified. Treatment of TB is a most serious challenge. Major problem of long-term use of existing anti –TB drugs are drug resistance and adverse effects. Drug resistant tuberculosis is widespread and is now a threat to tuberculosis control programme in many countries. Natural products derived from medicinal plants may play a significant role in discovery of new anti-TB drugs. Plants and their secondary metabolites include alkaloids, glycosides, tannins, phenolics, xanthones, quinones, sterols and triterpenoids are reported to have anti-tubercular activity comparable to the existing anti-tubercular drugs. Some of the Phyto molecules and plant extracts were found to be synergistically effective with existing anti TB drugs. Ayurvedic formulations have a significant role in the management of tuberculosis. They act as an adjuvant therapy and bioavailability enhancers. This review demonstrates that Plants, Secondary metabolites and Ayurvedic formulations have potential to cure tuberculosis, drug resistance tuberculosis and minimize adverse effects. They can be used as an alternative treatment for tuberculosis. Wed, 01 Jan 2020 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/8252 2020-01-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/8231 Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature Vora, Pratik A; Patel, Rakesh; Dharamsi, Abhay Background: Bortezomib is a reversible inhibitor of proteasome proteins in mammalian cells. Bortezomib is proven to be cytotoxic to a number of tumor cells by disrupting their normal homeostatic mechanism and thereby, causing cell death. Currently, Bortezomib is prescribed for patients with multiple myeloma and mantle cell lymphoma. Objective: This assessment highlights the overview of the recent patents of Bortezomib. This review includes patents grouped in sections like product patents, process patent, composition related patents as well as the treatment methodology. The objective of this article is to facilitate researchers with all existing patents at a single place. Methods: Data were searched from various online databases. In which, paid databases include SciFinder® and Orbit®. Free databases include Patentscope® (WIPO), Worldwide Espacenet® (EPO), Google Patents and InPASS (Indian patent database). Results: Several new processes and composition related patents of Bortezomib have been recently patented as its orange-book listed patents are going to soon expire during July 2022. Further, due to the problem of oxidation during development and long-term storage of Bortezomib formulation, a number of excipients are tried in these patents to stabilize the same. However, there is still a need for further development of an improved formulation of Bortezomib with better characteristics. Conclusion: Link: Extensive research has been carried out on various processes for preparing Bortezomib and the composition thereof. This type of dynamic research will clear the path for many generic players in the United States, which lead to the reduction of the price of the composition and thereby enhancing global health care at cheaper prices. Wed, 01 Jan 2020 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/8231 2020-01-01T00:00:00Z